High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.
Furuya K, Nakajima M, Tsunedomi R, Nakagami Y, Xu M, Matsui H, Tokumitsu Y, Shindo Y, Watanabe Y, Tomochika S, Maeda N, Iida M, Suzuki N, Takeda S, Hazama S, Ioka T, Hoshii Y, Ueno T, Nagano H.
Furuya K, et al.
BMC Cancer. 2024 Feb 2;24(1):165. doi: 10.1186/s12885-024-11924-4.
BMC Cancer. 2024.
PMID: 38308214
Free PMC article.